The US Food and Drug Administration (FDA) has granted 510(k) clearance for Profound Medical’s Thermal Boost module for use along with TULSA-PRO.

Surgeons can use the TULSA-PRO technology for ablating whole or partial-gland prostate tissue in patients with low, intermediate, or high-risk prostate cancer. It can also be used to treat benign prostatic hyperplasia (BPH).

The company intends to commercialise new clinically relevant modules under the ‘TULSA AI’ name brand.

Thermal Boost is the company’s first FDA-cleared TULSA AI module that allows surgeons to temporarily increase the ablation target temperature in prostate regions where advanced-stage cancer may be present.

This module, which already received a CE mark, is being used by up to 50% of TULSA patients in Europe.

Furthermore, the company is developing more TULSA AI modules, including one that will allow for the creation of an AI-driven treatment plan based on a successful physician design database.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The TULSA-PRO technology is also suitable for prostate cancer patients on active surveillance seeking treatment and relief from BPH symptoms.

Surgeons are using TULSA-PRO to treat prostates of varying sizes and shapes ranging from 20cc to 250cc for prostate disease treatment.

Profound CEO and chairman Arun Menawat said: “We believe that the TULSA technology can be used to treat up to 600,000 patients per year in the US and based on the utilisation data from Europe, Thermal Boost may have an application in the majority of late-stage disease cases.

“In addition, the feedback from European surgeons using the module indicates that Thermal Boost could significantly increase both the ease and speed of treatment in a certain subset of the patient population.”